A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma

LESSONS LEARNED. Clofarabine can be active in relapsed and refractory lymphoid malignancies on a weekly dosing schedule. Responses were seen in patients with T‐cell lymphomas, including cutaneous T‐cell lymphoma, but not in patients with aggressive B‐cell lymphomas. BACKGROUND. Clofarabine is a seco...

Descripción completa

Detalles Bibliográficos
Autores principales: Foss, Francine Marie, Parker, Terri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896711/
https://www.ncbi.nlm.nih.gov/pubmed/29438091
http://dx.doi.org/10.1634/theoncologist.2017-0658

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896711/
https://www.ncbi.nlm.nih.gov/pubmed/29438091
http://dx.doi.org/10.1634/theoncologist.2017-0658

Ejemplares similares